Find Olutasidenib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1887014-12-1, Ft-2102, Olutasidenib [usan], Olutasidenib (ft-2102), 0t4imt8s5z, 5-[[(1s)-1-(6-chloro-2-oxo-1h-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile
Molecular Formula
C18H15ClN4O2
Molecular Weight
354.8  g/mol
InChI Key
NEQYWYXGTJDAKR-JTQLQIEISA-N
FDA UNII
0T4IMT8S5Z

Olutasidenib
Olutasidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), with potential antineoplastic activity. Upon administration, olutasidenib specifically inhibits IDH1(R132), thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH(R132). IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.
1 2D Structure

Olutasidenib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-[[(1S)-1-(6-chloro-2-oxo-1H-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile
2.1.2 InChI
InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1
2.1.3 InChI Key
NEQYWYXGTJDAKR-JTQLQIEISA-N
2.1.4 Canonical SMILES
CC(C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N
2.1.5 Isomeric SMILES
C[C@@H](C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N
2.2 Other Identifiers
2.2.1 UNII
0T4IMT8S5Z
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

2. Ft-2102

2.3.2 Depositor-Supplied Synonyms

1. 1887014-12-1

2. Ft-2102

3. Olutasidenib [usan]

4. Olutasidenib (ft-2102)

5. 0t4imt8s5z

6. 5-[[(1s)-1-(6-chloro-2-oxo-1h-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile

7. (s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

8. Ft2102

9. 2-pyridinecarbonitrile, 5-(((1s)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-

10. 5-(((1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

11. 5-{[(1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

12. 5-[[(1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino]-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

13. Olutasidenib [inn]

14. Unii-0t4imt8s5z

15. Olutasidenib [who-dd]

16. Chembl4297610

17. Schembl17603134

18. Gtpl10319

19. Amy16919

20. Ex-a4523

21. Bdbm50506474

22. Example 26 [us9834539b2]

23. Nsc818621

24. S8949

25. Ft-2102ft-2102

26. Nsc-818621

27. Ac-36556

28. Hy-114226

29. Cs-0080183

30. D87221

31. 5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile

32. Pwv

2.4 Create Date
2016-04-09
3 Chemical and Physical Properties
Molecular Weight 354.8 g/mol
Molecular Formula C18H15ClN4O2
XLogP32.5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Exact Mass354.0883534 g/mol
Monoisotopic Mass354.0883534 g/mol
Topological Polar Surface Area85.2 Ų
Heavy Atom Count25
Formal Charge0
Complexity745
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 11738018

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3684

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-07-17

blank

02

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 10532047

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

blank

03

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 12053463

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

blank

04

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 10959994

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

blank

05

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 11497743

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3495

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

blank

06

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 10414752

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-18

blank

07

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 11376246

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3495

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

blank

08

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 10550098

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 215814

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-09-18

blank

09

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 11013734

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3495

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

blank

10

RIGEL PHARMS

arrow
BIO Partnering at JPM
Not Confirmed

RIGEL PHARMS

Country
arrow
BIO Partnering at JPM
Not Confirmed

OLUTASIDENIB

US Patent Number : 11013733

Drug Substance Claim :

Drug Product Claim :

Application Number : 215814

Patent Use Code : U-3496

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-05-16

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Olutasidenib Manufacturers

A Olutasidenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olutasidenib, including repackagers and relabelers. The FDA regulates Olutasidenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olutasidenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Olutasidenib Suppliers

A Olutasidenib supplier is an individual or a company that provides Olutasidenib active pharmaceutical ingredient (API) or Olutasidenib finished formulations upon request. The Olutasidenib suppliers may include Olutasidenib API manufacturers, exporters, distributors and traders.

Olutasidenib GMP

Olutasidenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Olutasidenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olutasidenib GMP manufacturer or Olutasidenib GMP API supplier for your needs.

Olutasidenib CoA

A Olutasidenib CoA (Certificate of Analysis) is a formal document that attests to Olutasidenib's compliance with Olutasidenib specifications and serves as a tool for batch-level quality control.

Olutasidenib CoA mostly includes findings from lab analyses of a specific batch. For each Olutasidenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Olutasidenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olutasidenib EP), Olutasidenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olutasidenib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty